Tumor necrosis α-blocking agent (Etanercept): A triple blind randomized controlled trial of its use in treatment of sciatica

Journal of Spinal Disorders and Techniques

Volumn 23, Issue 1, 2010, Pages 74-77

  Okoro, Tosan ^a   Tafazal, Suhayl I ^b   Longworth, Stephen ^a   Sell, Philip J ^a  

^a Department of Orthopaedics and Trauma ^*  (United Kingdom)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

Etanercept; Inflammation; Prolapsed intervertebral disc; Sciatica; Tumor necrosis a

Indexed keywords

ETANERCEPT; PLACEBO;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; INTERVERTEBRAL DISK HERNIA; ISCHIALGIA; LEG PAIN; LUMBAR DISK HERNIA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN ASSESSMENT; PHYSICAL DISABILITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; INTERVERTEBRAL DISK DISPLACEMENT; MALE; PAIN MEASUREMENT; PLACEBOS; RADICULOPATHY; RECEPTORS, TUMOR NECROSIS FACTOR; SAMPLE SIZE; SCIATICA; SPINAL NERVE ROOTS; SPONDYLOSIS; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 76649092954     PISSN: 15360652     EISSN: None     Source Type: Journal    
DOI: 10.1097/BSD.0b013e31819afdc4     Document Type: Article

References (18)

1. Watkins LR, Coehler LE, Relton J, et al. Mechanism of tumour necrosis factor alpha hyperalgesia. Brain Res. 1995;692:244-250.
2. Watkins LR, Maier SF, Groehler LE. Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states. Pain. 1995;63:289-302.
3. Watkins LR, Wiertelak EP, Goehler LE, et al. Characterization of cytokine-induced hyperalgesia. Brain Res. 1994;654:15-26.
4. Olmarker K, Rydevik B. Selective inhibition of TNF-alpha prevents nucleus pulposus-induced thrombus formation, intra-neural edema, and reduction of nerve conduction velocity: possible implications for future pharmacologic treatment strategies of sciatica. Spine. 2001; 26:863-869.
5. Tafazal SI, Sell PJ. Outcome measures in spinal surgery quantified: excellent, good, fair, and poor in terms of patient-completed tools. Eur Spine J. 2006;15:1653-1660.
6. Abuzakouk M, Feighery C, Jackson J. Tumour necrosis factor blocking agents: a new therapeutic modality for inflammatory disorders. Br J Biomed Sci. 2002;59:173-179.
7. Byrod G, Otani K, Olmarker K, et al. Short term epidural exposure to nucleus pulposus induces increased endoneural capillary permeability and reduction in spinal nerve root blood flow. Presented at the 44th Annual Meeting of the Orthopaedic Research Society, New Orleans, Louisiana, March 16-19, 1998.
8. Otani K, Arai I, Mao GP, et al. Nucleus pulposus-induced nerve root injury: the relationship between blood flow and nerve conduction velocity. Neurosurgery. 1999;45:614-618.
9. Olmarker K, Larsson K. Tumour necrosis factor alpha and nucleus pulposus-induced nerve root injury. Spine. 1998;23:2538-2544.
10. Tobinick EL, Britschgi-Davoodifar S. Peri-spinal TNF-alpha inhibition for discogenic pain. Swiss Med Wkly. 2003;133:170-177.
11. Karppinen J, Korhonen T, Malmivaara A et al. Tumor necrosis factor-alpha monoclonal antibody, infliximab, used to manage severe sciatica. Spine. 2003;28:750-753.
12. Korhonen T, Karppinen J, Paimela L et al. The treatment of disc herniation-induced sciatica with infliximab. One year follow-up results of FIRST II, a randomised controlled trial. Spine. 2006;31: 2759-2766.
13. Cohen SP, Wenzell D, Hurley RW, et al. A double-blind, placebocontrolled, dose-response pilot study evaluating intradiscal Etanercept in patients with chronic discogenic low back pain or lumbosacral radiculopathy. Anesthesiology. 2007;107: 99-105.
14. Moreland DW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomised, controlled trial. Ann Intern Med. 1999;130:478-486.
15. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumour necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253-259.
16. Xie W, Strong JA, Meij JT, et al. Neuropathic pain: early spontaneous afferent activity is the trigger. Pain. 2005;116: 243-256.
17. Weber H. Lumbar disc herniation: a controlled, prospective study with ten years of observation. Spine. 1983;8:131-140.
18. Peul WC, van Houwelingen HC, van den Hout WB, et al. Surgery versus prolonged conservative treatment for sciatica. N Engl J Med. 2007;356:2245-2256.